- Khiron applauds Colombia on becoming one of the first countries to extend national health insurance for patients to include medical cannabis as a first line therapy
- Leveraging Khiron’s status as a National Strategic Project, Khiron medical cannabis products and clinic services are now covered by health insurance companies in Colombia
- Over 94% of Colombians have health insurance policies
- More than 1,000 Khiron prescriptions issued in the last quarter have already qualified for this insurance coverage, removing economic barriers and increasing patient access to the Company’s products and services
- The Government of Colombia has included THC and CBD products in its health insurance directive following an analysis of efficacy and quality of legal medical cannabis and the market potential
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that as a result of strong clinical evidence, the Company’s National Strategic Project status, and a directive from the Government of Colombia its medical cannabis products and clinic services are now covered by the country’s major health insurance providers, including medical cannabis as a first line therapy. In Colombia more than 94% of the population have health insurance.
“We see the inclusion of our products and services under health insurance policies as a significant driver of revenue opportunities for Khiron in Colombia , and a validation of our clinic model and the potential for market growth in the country. Importantly, this will allow more Colombians access to benefit from our medical cannabis products and clinic resources,” commented Alvaro Torres , Khiron CEO and Director.
“Since becoming the first company to fill cannabis prescriptions in Colombia , 92% of our patients have reported an improvement in their primary conditions after four months of treatment with Khiron products. We look forward to improving the quality of life of even more patients who are now able to access medical cannabis through insurance coverage,” added Mr. Torres.
With today’s news, Colombia joins an exclusive list of countries offering health insurance coverage for medical cannabis, including Germany and the Czech Republic . In the first half of 2020, over €75 million worth of medical cannabis products were sold in Germany to an estimated patient population of approximately 120,000 (Source: Prohibition Partners). Revisions to German laws in 2017 had wide ranging implications for the country’s cannabis market requiring health insurers to cover the costs of the prescription except in exceptional circumstances, with over 60% of patients receiving reimbursement from their health insurance provider. In the Czech Republic , which recently included extended health insurance for medical cannabis, sales in the first four months of 2020 increased threefold over the same period in 2019.
Under the Colombian program, Khiron clinics receive government and insurance company authorization to fill patient prescriptions for magistral preparations; subsequently, the Company is reimbursed once products have been dispensed to the patients. This will allow a greater number of Colombian patients to have access to Khiron’s medical cannabis products and clinical services. Khiron’s clinic strategy continues to provide cost-effective access to patients, while allowing the Company to generate medical evidence and deliver an unparalleled physician and patient experience. With a large patient base and growing network of physicians trained in the prescription of medical cannabis, Khiron is uniquely positioned to take advantage of the insurance policy change.
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America , and operational activity in Europe and North America . Khiron is the leading cannabis company in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Peru and has a presence in Mexico , Uruguay , UK, Spain and also in Germany , where it is positioned to begin sales of medical cannabis.
Leveraging its first-mover advantage and patient-oriented approach, Khiron combines global scientific expertise, product innovation, agricultural infrastructure, wholly-owned medical clinics, and online doctor education programs to drive prescription and brand loyalty to address priority medical conditions. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia , with Kuida TM now marketed in multiple jurisdictions in Latin America , the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres , together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com . The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
View original content to download multimedia: http://www.prnewswire.com/news-releases/khiron-medical-cannabis-products-now-qualify-for-national-insurance-coverage-in-colombia-301187052.html
SOURCE Khiron Life Sciences Corp.
News Provided by PR Newswire via QuoteMedia
Khiron Life Sciences
Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.
Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).
Seattle Area Grocery Chain Metropolitan Market to Begin Carrying KOIOS and Fit Soda on March 22, 2021
Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.
Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.
Pineapple Express Delivery Partners with CannTrust to Offer Same-Day and Next-Day Delivery for estoraTM Medical Cannabis Patients in Ontario
Ensuring estoraTMpatients have seamless access to their high-quality medical cannabis products
World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announce that its subsidiary Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, has partnered with CannTrust Inc. to bring same-day and next-day delivery to estoraTM medical cannabis patients in Ontario
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.